Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Nykode Therapeutics AS (VACBF) - Net Assets
Latest net assets as of December 2025: $91.54 Million USD
Based on the latest financial reports, Nykode Therapeutics AS (VACBF) has net assets worth $91.54 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($99.95 Million) and total liabilities ($8.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $91.54 Million |
| % of Total Assets | 91.58% |
| Annual Growth Rate | 20.14% |
| 5-Year Change | -52.83% |
| 10-Year Change | N/A |
| Growth Volatility | 186.44 |
Nykode Therapeutics AS - Net Assets Trend (2019–2025)
This chart illustrates how Nykode Therapeutics AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nykode Therapeutics AS (2019–2025)
The table below shows the annual net assets of Nykode Therapeutics AS from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $91.54 Million | -32.80% |
| 2024-12-31 | $136.21 Million | -20.46% |
| 2023-12-31 | $171.26 Million | +9.07% |
| 2022-12-31 | $157.02 Million | -19.09% |
| 2021-12-31 | $194.06 Million | +8.50% |
| 2020-12-31 | $178.85 Million | +487.61% |
| 2019-12-31 | $30.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nykode Therapeutics AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1172100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $112.72 Million | 123.14% |
| Total Equity | $91.54 Million | 100.00% |
Nykode Therapeutics AS Competitors by Market Cap
The table below lists competitors of Nykode Therapeutics AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Groundhog Inc.
TW:6906
|
$35.05 Million |
|
Hancock & Gore Ltd
AU:HNG
|
$35.05 Million |
|
Cosmax
KO:044820
|
$35.06 Million |
|
SMO
BK:SMO
|
$35.06 Million |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
$35.04 Million |
|
ABITARE IN S.P.A.
F:1BN
|
$35.04 Million |
|
Melcor Real Estate Investment Trust
TO:MR-UN
|
$35.04 Million |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
$35.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nykode Therapeutics AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 136,214,000 to 91,537,000, a change of -44,677,000 (-32.8%).
- Net loss of 12,240,000 reduced equity.
- Dividend payments of 32,279,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.24 Million | -13.37% |
| Dividends Paid | $32.28 Million | -35.26% |
| Other Changes | $-158.00K | -0.17% |
| Total Change | $- | -32.80% |
Book Value vs Market Value Analysis
This analysis compares Nykode Therapeutics AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.02x to 0.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.11 | $0.22 | x |
| 2020-12-31 | $0.63 | $0.22 | x |
| 2021-12-31 | $0.67 | $0.22 | x |
| 2022-12-31 | $0.53 | $0.22 | x |
| 2023-12-31 | $0.52 | $0.22 | x |
| 2024-12-31 | $0.42 | $0.22 | x |
| 2025-12-31 | $0.28 | $0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nykode Therapeutics AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-13.37%) is below the historical average (-6.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -35.75% | -19622.90% | 0.00x | 1.09x | $-13.92 Million |
| 2020 | 83.74% | 69.66% | 0.93x | 1.29x | $131.89 Million |
| 2021 | -4.85% | -27.72% | 0.13x | 1.37x | $-28.82 Million |
| 2022 | -27.22% | -596.30% | 0.03x | 1.41x | $-58.44 Million |
| 2023 | -20.53% | -272.47% | 0.06x | 1.22x | $-52.28 Million |
| 2024 | -28.50% | -447.30% | 0.06x | 1.13x | $-52.44 Million |
| 2025 | -13.37% | 0.00% | 0.00x | 1.09x | $-21.39 Million |
Industry Comparison
This section compares Nykode Therapeutics AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nykode Therapeutics AS (VACBF) | $91.54 Million | -35.75% | 0.09x | $35.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |